OpenAI has launched GPT-Rosalind, a new artificial intelligence (AI) model built to support scientific and lab research. This marks the company’s first AI system tailored exclusively for life sciences research, with a focus on biology, drug discovery, and translational medicine.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade NVDAOpenAI Says GPT-Rosalind Will Speed Early Research
OpenAI described GPT-Rosalind as a life sciences model, designed to provide stronger foundational reasoning across fields such as chemistry, protein engineering, and genomics. The firm noted that drug development in the U.S. takes about 10 to 15 years, with research slowed by complex workflows involving large volumes of data, the literature, and experiments.
As a result, OpenAI believes its AI model could help researchers speed up early-stage discovery by helping them accurately put evidence together, generate hypotheses, plan experiments, and support other multi-step research tasks. The private company named GPT-Rosalind after British chemist Rosalind Franklin, whose work helped reveal the structure of DNA and shaped modern molecular biology.
GPT-Rosalind Launches in ChatGPT and Codex
OpenAI’s GPT-Rosalind launch comes as demand for AI tools that speed up drug discovery has increased among pharmaceutical companies, academic institutions, and biotech firms. The company said the model is now available as a research preview in ChatGPT, Codex, and its API for selected customers under its trusted access system.
In addition, the firm is rolling out a free Life Sciences research plugin for Codex that links scientists to more than 50 tools and data sources. Meanwhile, OpenAI is also working with partners including Amgen (AMGN), Moderna (MRNA), and Thermo Fisher Scientific (TMO) to deploy GPT-Rosalind across research and development workflows.
What is the Best AI Stock to Invest in Right Now?
According to TipRanks Stocks Comparison Center, Nvidia (NVDA), Micron (MU), Alphabet Class A (GOOGL), Meta Platforms (META), and Microsoft (MSFT) rank as the best-performing AI stocks right now. Based on Wall Street analysts’ ratings over the past three months, all carry a “Strong Buy” consensus with notable upsides.
